Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Further Strengthens US Patent Estate

Silence Therapeutics
Posted on: 14 Sep 17

Silence Therapeutics plc, AIM:SLN (“Silence” or “the Company”) a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that the US Patent and Trade Mark Office has issued a notice of allowance for US patent application 15/594,438. A further key US patent 9,758,784 is to be granted tomorrow to Silence.

 

Silence has made the relevant payment of grant fees for US patent application 15/594,438 and normal practice is that the granted patent will now be issued by the US Patent and Trade Mark Office.

 

As previously mentioned on 31 July 2017, the US Patent and Trade Mark Office issued a notice of allowance for US patent application 15/589,971, which will issue tomorrow as US patent 9,758,784.

 

The allowed claims of both patents when granted provide Silence with further protection for its innovative chemical modification technology in the US.

 

Silence believes these allowed claims are relevant to third party medicines in ongoing clinical trials.

 

Ali Mortazavi, Chief Executive Officer of Silence Therapeutics, commented:

 

“This notice of allowance and grant in the US provides further protection for our US patent estate. Combined with our other recently allowed US patent applications, we will have ten granted US patents, one US patent application, three granted European patents and four European patent applications encompassing our chemical modification technology. Our chemical modification patent portfolio also encompasses patents and patent applications in the following countries: Australia, Brazil, Canada, China, Israel, India, Japan, Korea, Mexico and South Africa. We continue to believe that several third party late-stage clinical RNAi candidates require licences under our patent portfolio and that such licences could have a material financial effect on Silence.”

 

Enquiries:

 

Silence Therapeutics plc

 

Ali Mortazavi, Chief Executive Officer

David Ellam, Chief Financial Officer

Tel:  +44 (0)20 3457 6900

 

 

Peel Hunt LLP (Nominated Adviser and Broker)

 

James Steel/Oliver Jackson

 

Tel:  +44 (0)20 7418 8900

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 14/09/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.